Your browser doesn't support javascript.
loading
The natural history, clinical outcomes, and genotype-phenotype relationship of otoferlin-related hearing loss: a systematic, quantitative literature review.
Ford, Charles L; Riggs, William J; Quigley, Tera; Keifer, Orion P; Whitton, Jonathon P; Valayannopoulos, Vassili.
Affiliation
  • Ford CL; Decibel Therapeutics, Inc, Boston, MA, USA.
  • Riggs WJ; Decibel Therapeutics, Inc, Boston, MA, USA.
  • Quigley T; Decibel Therapeutics, Inc, Boston, MA, USA.
  • Keifer OP; Decibel Therapeutics, Inc, Boston, MA, USA.
  • Whitton JP; Decibel Therapeutics, Inc, Boston, MA, USA.
  • Valayannopoulos V; Decibel Therapeutics, Inc, Boston, MA, USA. vvalayannopoulos@decibeltx.com.
Hum Genet ; 142(10): 1429-1449, 2023 Oct.
Article in En | MEDLINE | ID: mdl-37679651
ABSTRACT
Congenital hearing loss affects one in 500 newborns. Sequence variations in OTOF, which encodes the calcium-binding protein otoferlin, are responsible for 1-8% of congenital, nonsyndromic hearing loss and are the leading cause of auditory neuropathy spectrum disorders. The natural history of otoferlin-related hearing loss, the relationship between OTOF genotype and hearing loss phenotype, and the outcomes of clinical practices in patients with this genetic disorder are incompletely understood because most analyses have reported on small numbers of cases with homogeneous OTOF genotypes. Here, we present the first systematic, quantitative literature review of otoferlin-related hearing loss, which analyzes patient-specific data from 422 individuals across 61 publications. While most patients display a typical phenotype of severe-to-profound hearing loss with prelingual onset, 10-15% of patients display atypical phenotypes, including mild-to-moderate, progressive, and temperature-sensitive hearing loss. Patients' phenotypic presentations appear to depend on their specific genotypes. For example, non-truncating variants located in and immediately downstream of the C2E calcium-binding domain are more likely to produce atypical phenotypes. Additionally, the prevalence of certain sequence variants and their associated phenotypes varies between populations due to evolutionary founder effects. Our analyses also suggest otoacoustic emissions are less common in older patients and those with two truncating OTOF variants. Critically, our review has implications for the application and limitations of clinical practices, including newborn hearing screenings, hearing aid trials, cochlear implants, and upcoming gene therapy clinical trials. We conclude by discussing the limitations of available research and recommendations for future studies on this genetic cause of hearing loss.
Subject(s)

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Deafness / Hearing Loss, Central / Hearing Loss Type of study: Guideline / Risk_factors_studies Limits: Aged / Humans / Newborn Language: En Journal: Hum Genet Year: 2023 Type: Article Affiliation country: United States

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Deafness / Hearing Loss, Central / Hearing Loss Type of study: Guideline / Risk_factors_studies Limits: Aged / Humans / Newborn Language: En Journal: Hum Genet Year: 2023 Type: Article Affiliation country: United States